MediPharm Labs (MediPharm Labs) ROCE % : -27.07% (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is MediPharm Labs ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. MediPharm Labs's annualized ROCE % for the quarter that ended in Mar. 2024 was -27.07%.

MediPharm Labs ROCE % Historical Data

The historical data trend for MediPharm Labs's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MediPharm Labs ROCE % Chart

MediPharm Labs Annual Data

Trend

Sep17

Sep18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

10.24

-55.81

-49.81

-41.42

-23.97

MediPharm Labs Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-22.39	-18.37	-28.53	-23.26	-27.07

MediPharm Labs ROCE % Calculation

MediPharm Labs's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-9.685	/	( ( (48.211 - 6.961)	+	(47.657 - 8.097) )	/ 2 )
	=	-9.685	/	( (41.25	+	39.56)	/ 2 )
	=	-9.685	/	40.405
	=	-23.97 %

MediPharm Labs's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-10.344	/	( ( (47.657 - 8.097)	+	(45.246 - 8.372) )	/ 2 )
	=	-10.344	/	( ( 39.56	+	36.874 )	/ 2 )
	=	-10.344	/	38.217
	=	-27.07 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

MediPharm Labs (OTCPK:MEDIF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

MediPharm Labs ROCE % Related Terms

Thank you for viewing the detailed overview of MediPharm Labs's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

MediPharm Labs (MediPharm Labs) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » MediPharm Labs Corp (OTCPK:MEDIF) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

MLZ:Germany LABS:Canada

Address

151 John Street, Barrie, ON, CAN, L4N 2L1

Website

https://www.medipharmlabs.com

MediPharm Labs Corp is a pharmaceutical company specializing in precision-based cannabinoids. The Company operates in one reportable segment, the production and sales of cannabis extracts and derivative products. Through its wholesale and white-label platforms, MediPharm Labs formulates, develops, processes, packages, and distributes cannabis extracts and cannabinoid-based products to domestic and international markets. Geographically company has a presence in Canada, Australia, Germany, and other countries and the majority of revenue derives from Canada.